Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 50 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748260 | De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast(neoDIRHP) | not yet recruiting | Phase 3 | 592 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 5, 2026 |
| clinicaltrials |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | active not recruiting | Phase 3 | 608 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer(BEGONIA) | active not recruiting | Phase 1 / Phase 2 | 243 | AstraZenecaINDUSTRY | 6 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07078604 | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study(GBCF003) | recruiting | Phase 1 / Phase 2 | 30 | Liu ShuOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC(NeoASPECT) | not yet recruiting | Phase 2 | 110 | University of Kansas Medical CenterOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT03077776 | Tracking Triple-negative Breast Cancer Evolution Through Therapy(TRACERX-TNBC) | active not recruiting | N/A | 149 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04360330 | SABER Study for Selected Early Stage Breast Cancer(SABER) | recruiting | N/A | 18 | University of MiamiOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)(ADAPT-TN-III) | recruiting | Phase 3 | 348 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07151586 | Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer(ALTER) | not yet recruiting | Phase 2 | 260 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | terminated | Early Phase 1 | 15 | Wake Forest University Health SciencesOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04052555 | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04345913 | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04521764 | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer | recruiting | Phase 1 | 54 | Mayo ClinicOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | suspended | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02654119 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy(AIPAC-003) | terminated | Phase 2 / Phase 3 | 72 | Immutep S.A.S.INDUSTRY | 5 | Jul 30, 2026 | clinicaltrials |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors(PROFFi) | recruiting | Phase 2 | 164 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06445400 | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 2 | 83 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06347068 | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | recruiting | Phase 1 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT04243616 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer(CemiHALT) | active not recruiting | Phase 2 | 36 | Medical College of WisconsinOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06184750 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06604858 | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer(TELESCOPE) | completed | Phase 2 | 31 | MedSIROTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729046 | Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02252887 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02942355 | Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC(ETNA) | recruiting | Phase 2 | 354 | UNICANCEROTHER | 2 | Jul 24, 2026 | clinicaltrials |
| NCT06295744 | Outcomes and Cosmesis With Whole Breast Irradiation and Boost | active not recruiting | N/A | 50 | University of Wisconsin, MadisonOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07458113 | Sac-TMT for Active TNBC Brain Metastases(BERLIN) | not yet recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726342 | SMP-656 for HER2-Positive Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Chengdu SciMount Pharmatech Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | active not recruiting | Phase 3 | 466 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 20 | Jul 23, 2026 | clinicaltrials |
| NCT04595435 | IORT-Breast at Medical Center Navicent Health(IORT-Breast) | active not recruiting | — | 94 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06026657 | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 42 | Margaret Gatti-MaysOTHER | 1 | Jul 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials